CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Aortic Valve Stenosis Treatment Disparities in the Underserved JACC Council Perspectives 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
|<<... 95 96 97 98 99 100 101 ...>>|

Review Article2018 Dec 8;22:39-45.

JOURNAL：Int J Cardiol Heart Vasc. Article Link

Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies

Cerrato E, Bianco M, Bagai A et al. Keywords: Acute coronary syndrome; Clopidogrel; Novel P2Y12 inhibitors; Prasugrel; Switching; Ticagrelor

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top